Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Recap: SkyWest Q4 Earnings

SkyWest (NASDAQ:SKYW) reported its Q4 earnings results on Thursday, February 1, 2024 at 04:01 PM. Here’s what investors…
byBenzinga Insights
February 1, 2024
1 minute read
Total
0
Shares
0
0
0
0
0
0

SkyWest (NASDAQ:SKYW) reported its Q4 earnings results on Thursday, February 1, 2024 at 04:01 PM.

Here’s what investors need to know about the announcement.

Earnings

SkyWest beat estimated earnings by 180.0%, reporting an EPS of $0.42 versus an estimate of $0.15.

Revenue was up $70.54 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.15 which was followed by a 11.62% increase in the share price the next day.

Here’s a look at SkyWest’s past performance:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate 0.40 -0.45 -0.56 0.08
EPS Actual 0.55 0.35 -0.45 -0.93
Revenue Estimate 756.15M 717.66M 668.62M 711.44M
Revenue Actual 766.17M 725.64M 691.83M 681.25M

To track all earnings releases for SkyWest visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Aurora Touts 41% YoY Increase In International Medical Cannabis Q3 Revenue, Expands In Australia Via New Acquisition

By Jelena Martinovic
February 8, 12:04 PM
Canadian medical cannabis company Aurora Cannabis reported its financial and operational results for Q3 2024. Net revenue increased to CAD64.4m ($42m), up from CAD61.1m in the same quarter the previous year. Medical cannabis net revenue rose by 16% to CAD45.1m, representing 70% of Aurora's consolidated net revenue. Gross profit reached CAD19.8m, up from CAD3.7m in Q3 2022, with adjusted gross profit before fair value adjustments increasing to CAD32.4m from CAD28m. The company recorded a CAD25.5m net loss compared to CAD67.2m in the same quarter in the previous year. Adjusted EBITDA came in at CAD4.3m, up from CAD3m. Miguel Martin, CEO of Aurora, said the company's international medical net revenue had seen year-on-year growth of 41%.

ACB